Next 10 |
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved larg...
2024-07-15 07:31:03 ET More on Sol-Gel Technologies Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Financial information for Sol-Gel Technologies Read the full article on Seeking Alpha For...
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
2024-05-28 07:16:25 ET More on Sol-Gel Technologies Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M Read the full article on Seeking Alpha For further details see: Sol-Gel Technologies gets non-compliance notice from Na...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...
2024-05-20 13:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sol-Gel Technologies (NASDAQ: SLGL ) just reported results for the first quarter of 2024. Sol-Gel Technologies reported earnings per share of -23 cents. This was below the...
2024-05-20 09:42:03 ET More on Sol-Gel Technologies Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Finan...
Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO ® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $ 1 1...
2024-05-20 01:30:00 ET Summary Takeda Pharmaceutical acquired global rights to an Alzheimer’s therapy developed by Switzerland’s AC Immune SA for $100 million upfront and up to $2.1 billion in milestone payments. Zai Lab reported China’s NMPA approved Augtyro ...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
NESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved larg...
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...